Send Inquiry

Request To Call Back

Kadcyla 100mg injection

Name: Kadcyla 100mg injection
Brand: K. K. PHARMA SOLUTIONS

Get a Price/Quote

MOQ : 10 Boxes

Kadcyla 100mg injection Specification

Origin of Medicine
Switzerland

Salt Composition
Trastuzumab emtansine

Indication
Treatment of adults with HER2-positive, unresectable or metastatic breast cancer

Life Span
Refer to expiry date on vial (typically 24 months from manufacture)

Brand Name
Kadcyla

Packaging Type
Vial

Pacakaging (Quantity Per Box)
1 vial

Dosage Form
Lyophilized powder for concentrate for solution for infusion

Drug Type
Prescription only, anticancer biological

Ingredients
Trastuzumab emtansine (Kadcyla) 100mg

Physical Form
Injection

Function
Anti-cancer (antineoplastic), HER2-targeted therapy

Recommended For
HER2-positive metastatic breast cancer in adults

Dosage
As directed by physician; typically intravenous infusion every 3 weeks

Dosage Guidelines
Administer under supervision of oncologist or qualified healthcare professional

Suitable For
Adults only

Quantity
1 vial per box

Storage Instructions
Store at 2C to 8C. Do not freeze.

Reconstitution Instructions
Reconstitute with sterile water for injection as per instructions

Concentration
100mg/vial

Side Effects
Fatigue, nausea, musculoskeletal pain, thrombocytopenia, increased liver enzymes

Therapeutic Class
Antineoplastic agents, Antibody-drug conjugate

Contraindications
Severe hypersensitivity to the active substance or to any of the excipients

Route of Administration
Intravenous infusion

Prescription Required
Yes

Colour
White to off-white lyophilized powder

Marketed By
Roche

Registration Status
Approved by regulatory agencies like US FDA, EMA, and CDSCO for indicated use

Caution
Monitor liver function, platelet counts, and cardiac function during therapy

About Kadcyla 100mg injection

Kadcyla 100mg injection, a best-seller in HER2-targeted therapies, is the latest splendiferous innovation in the antineoplastic class, featuring trastuzumab emtansine. Manufactured by Roche, this fresh and unparalleled antibody-drug conjugate is available as a white to off-white lyophilized powder for intravenous infusion. With inestimable efficacy against HER2-positive metastatic breast cancer in adults, Kadcyla is approved by regulatory agencies like the US FDA, EMA, and CDSCO. Prescription is mandatory; monitoring of liver, cardiac, and blood parameters is advised during treatment. Store at 2C-8C.

Kadcyla 100mg: Indications, Unique Benefits & Application

Kadcyla 100mg injection is indicated for the treatment of adults with HER2-positive, unresectable or metastatic breast cancer. Its application is exclusively for human oncology, providing a targeted approach with inestimable clinical benefit. What gives Kadcyla unparalleled recognition is its design as an antibody-drug conjugate, combining precise cancer cell targeting with potent anticancer action. This competitive advantage translates into improved outcomes for patients when compared to traditional antineoplastic treatments.

Payment Terms, Export Markets & Supply Efficiency of Kadcyla 100mg

Expenditure for Kadcyla 100mg is determined by healthcare institutions, with payment terms tailored to bulk buyers and hospital procurement agencies. Shipped goods are handled with utmost care and only handed over to certified importers and suppliers across international markets. Roche ensures a steady supply ability, supporting demand in major export destinations such as Europe, the Middle East, and Southeast Asia, making Kadcyla a preferred choice among global oncology therapies.

FAQ's of Kadcyla 100mg injection:

Q: How should Kadcyla 100mg injection be administered?

A: Kadcyla 100mg must be reconstituted with sterile water for injection and administered as an intravenous infusion under the supervision of an oncologist or a qualified healthcare professional.

Q: What are the main benefits of using Kadcyla 100mg injection?

A: Kadcyla 100mg offers a HER2-targeted therapy for adults with metastatic breast cancer, delivering potent and precise anticancer action while minimizing off-target effects compared to traditional chemotherapy.

Q: When is Kadcyla 100mg injection typically used in cancer treatment?

A: Kadcyla 100mg is recommended for adults with HER2-positive, unresectable or metastatic breast cancer, especially in cases where prior HER2 therapy and chemotherapy have not achieved the desired response.

Q: Where is Kadcyla 100mg registered and approved for use?

A: Kadcyla 100mg is approved by leading regulatory agencies, including the US FDA, European Medicines Agency (EMA), and CDSCO in India, affirming its safety and efficacy.

Q: What precautions are necessary during the usage of Kadcyla 100mg injection?

A: Patients receiving Kadcyla should have regular monitoring of liver function, platelet counts, and cardiac function to ensure safety during therapy.

Tell us about your requirement